Biotech Strategy Blog
Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy
-
Insights on a novel emerging cancer target
-
Biotechs beating ADCs at the own game
-
Three Times A Charm
-
A novel bispecific ADC to watch out for
-
The Swiss Army Knife of Cancer Drugs
-
Big Pharma’s Next Big Bet
-
Degrading Expectations – BTK’s New Challenge
-
The ADC Frontier: Are We Ready for the Next Leap?
-
Beyond the Topo-I Rush: Finding Space in a Crowded ADC Landscape